Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
Biogen Idec and AbbVie announced positive top-line results from the…
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...